Clinical Trial Update: Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy [Phase 2]

View source ↗

Summary

Phase 2 trial update on SUBLIVAC Phleum for grass pollen allergy shows efficacy and safety data, completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Allergic Rhinoconjunctivitis

Drugs mentioned

• SUBLIVAC Phleum (null)

Snippet

Sponsor: HAL Allergy | Conditions: Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Status: COMPLETED | Results posted: 2019-09-13